First look at the only randomized trial of a booster vaccine data (Pfizer) today cdc.gov/vaccines/acip/…
95% efficacy vs symptomatic infections, consistent across all age, sex, race, ethnicity and comorbid condition subgroups
Benefit seen very early
95% efficacy vs symptomatic infections, consistent across all age, sex, race, ethnicity and comorbid condition subgroups
Benefit seen very early
Primary efficacy endpoint: 6 (booster) vs 123 events (placebo)
Solid safety profile
Solid safety profile
Side by side event curves for the original Pfizer vaccine trial vs the Booster trial
You can see the curves diverge about a week earlier with a booster, ~14 vs 7 days, which aligns with much faster induction of neutralizing antibodies
You can see the curves diverge about a week earlier with a booster, ~14 vs 7 days, which aligns with much faster induction of neutralizing antibodies
You get to pick the blue line or the red line
Boosters (3rd shots)
How to avoid confusion and align with the data
washingtonpost.com/health/2021/11…
or
How to engender confusion and disregard the evidence
wsj.com/articles/covid… @CDCDirector
How to avoid confusion and align with the data
washingtonpost.com/health/2021/11…
or
How to engender confusion and disregard the evidence
wsj.com/articles/covid… @CDCDirector
Take a look at the data for people age 18- 55 in this, the only randomized trial (and N>10,000) of a booster vs placebo. Let's make believe @CDCgov that only people >age 50 "should" derive benefit vs symptomatic infections. The primary efficacy endpoint of all vaccine trials.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
